Overall survival (absolute effect size estimates based on survival rate at 12 months) · participants with advanced hepatocellular carcinoma
It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes overall survival (absolute effect size estimates based on survival… compared with best supportive care alone (very low certainty).
1 finding from 1 review
Proportion of people with ≥ 1 serious adverse events (at 20 months) · participants with advanced hepatocellular carcinoma
It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes proportion of people with ≥ 1 serious adverse events (at 20 months) compared with best supportive care alone (very low certainty).
1 finding from 1 review
Health‐related quality of life · participants with advanced hepatocellular carcinoma
1 finding from 1 review
Disease progression · participants with advanced hepatocellular carcinoma
It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes proportion of people with disease progression compared with best supportive care alone (very low certainty).
1 finding from 1 review
Adverse events considered non‐serious · participants with advanced hepatocellular carcinoma
It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes adverse events considered non‐serious (number of participants) compared with best supportive care alone (very low certainty).
1 finding from 1 review
Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma
It is very uncertain whether adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver… changes adverse events considered non‐serious (number of participants) compared with liver transplantation (very low certainty).
1 finding from 1 review
All‐cause mortality · participants with unresectable hepatocellular carcinoma
Double‐dose adenovirus‐thymidine kinase with ganciclovir… may leads to lower all‐cause mortality compared with liver transplantation (low certainty).
1 finding from 1 review
Proportion of people with ≥ 1 serious adverse events during treatment · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease progression · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival Censored · participants with unresectable hepatocellular carcinoma
It is very uncertain whether recombinant human adenovirus‐p53 and hydroxycamptothecin (rAd‐p53/HCT) changes overall survival Censored compared with hydroxycamptothecin (very low certainty).
1 finding from 1 review
Proportion of people with ≥ 1 serious adverse events · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease progression · participants with unresectable hepatocellular carcinoma
It is very uncertain whether recombinant human adenovirus‐p53 and hydroxycamptothecin (rAd‐p53/HCT) changes proportion of people with disease progression compared with hydroxycamptothecin (very low certainty).
1 finding from 1 review
Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma
1 finding from 1 review
Overall survival · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of people with ≥ 1 serious adverse events · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease progression · participants with unresectable hepatocellular carcinoma
It is very uncertain whether recombinant human adenovirus‐p53 and 5‐fluorouracil (rAd‐p53/5‐Fu)… changes proportion of people with disease progression compared with transarterial chemoembolisation (very low certainty).
1 finding from 1 review